<DOC>
	<DOCNO>NCT00646035</DOCNO>
	<brief_summary>To determine safety efficacy paricalcitol capsule compare placebo treatment secondary hyperparathyroidism decrease serum intact parathyroid hormone level end stage renal disease subject peritoneal dialysis .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Paricalcitol Capsules Reducing Serum Intact Parathyroid Hormone Levels End Stage Renal Disease Subjects Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Subject great equal 18 year . Subject diagnose ESRD must continuous PD 7 day per week least 2 month prior Screening Phase . If female , subject either childbearing potential childbearing potential practice one recommend method birth control . If female , subject must negative serum pregnancy test prior treatment . If female , subject breastfeeding . Subject undergoing full PD regimen expect remain PD regimen duration study . For subject take phosphate binder prior therapy , subject stable type phosphate binder least 4 week prior PreTreatment Phase . For entry Pretreatment Phase subject must : Calcium level less equal 10.5 mg/dL Ca x P level less equal 65 . For entry Treatment Phase subject must : iPTH great equal 300 pg/mL , calcium level 8.0 10.5 mg/dL , inclusive , Ca x P less equal 65 . Subject voluntarily sign date IRB approve informed consent . Subject history allergic reaction significant sensitivity drug similar study drug Subject active peritonitis within 1 month prior screen phase . Subject one episode peritonitis within 4 month prior screen phase . Subject receive partial parathyroidectomy within 1 year prior screen phase . Subject acute renal failure within 3 month screen phase . Subject chronic gastrointestinal disease . Subject take aluminumcontaining phosphate binder great 3 week last 3 month prior screen phase require medication great 3 week study . Subject current malignancy clinically significant liver disease . Subject history drug alcohol abuse within 6 month prior screen phase . Subject evidence poor compliance diet , medication , PD . Subject participate investigational drug device study within 4 week prior treatment phase . Subject take maintenance calcitonin , glucocorticoid , drug may affect calcium bone metabolism , females stable estrogen and/or progestin therapy . For reason , subject consider investigator unsuitable candidate receive paricalcitol capsule . Subject know HIV positive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>